BMY
Bristol-Myers Squibb Company
14
Dormant
Bristol-Myers Squibb's dormant conviction hides a compelling setup amid risk-off rotation and high margins.
The thesis
Bristol-Myers Squibb operates in the large-cap pharma layer with a gross margin of 70.16% and revenue growth of 5.7% YoY. The company's conviction score is 15/100, indicating a dormant setup. Analyst consensus is BUY, despite the low conviction. The high net margin of 18.87% suggests strong profitability.
Why now
The risk-off rotation is inactive, and the BoJ Interest Rate Decision may trigger market movements. With a P/E of 13.9x, the company's valuation is relatively reasonable.
What to watch
Revenue growth over the next quarter and updates on ongoing trials will be crucial in confirming or denying the thesis. Changes in drug pricing policy will also be a key indicator to watch.
Key risks
Drug pricing policy changes and trial failures are recurring shocks that could impact the company's performance. A significant decline in revenue growth could invalidate the thesis.
Theme exposure
Healthcare, Biotech & Devices
DirectBristol-Myers Squibb Company sits in the large-cap pharma layer of the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
Market intelligence only. Not financial advice. Not a recommendation.